Keywords

• 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d₃)pyridazine-3-carboxamide
• 1609392-27-9
• Deucravacitinib Impurity

Quick Details

• ProName: Deucravacitinib Impurity ;1609392-27-9
• CasNo: 1609392-27-9
• Molecular Formula: C20H19D3N8O3
• Appearance: White to off white powder
• Application: experiment research
• DeliveryTime: prompt delivery
• PackAge: Food bags, aluminum foil bags
• Port: Shenzhen/hongkong
• ProductionCapacity: 5000 Gram/Year
• Purity: 99%+ HPLC
• Storage: cool and dry
• Transportation: DHL,EMS,TNT,UPS,EMS,by air,by sea;
• LimitNum: 10 Milligram
• Moisture Content: 0.1%
• Impurity: 0.1%

Superiority

Advantages

• High-Purity Reference Standard：Confirmed by HPLC (≥99.0%), NMR (1H, 13C), HRMS, and elemental analysis, suitable for Deucravacitinib impurity analysis and quality control.

• Stability Assurance：Stable for 36 months at -20℃ under light-protected, sealed storage; degradation rate <0.3% in methanol-water solution within 6 months.

Details

Deucravacitinib Impurity ;1609392-27-9

Product Information

• Product Code：D084000

• English Name：Deucravacitinib

• English Alias：6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide

• CAS No.：1609392-27-9

• Molecular Formula：C??H??D?N?O?

• Molecular Weight：425.46

Applications

• Drug Development：As a novel tyrosine kinase 2 (TYK2) inhibitor, it is used in the development of drugs for autoimmune diseases such as psoriasis. It regulates the immune response and reduces the release of inflammatory factors by inhibiting the TYK2 signaling pathway.

• Preclinical Research：In pharmacokinetic studies, its deuterated structure is utilized to explore the metabolic pathways and elimination patterns in vivo, optimizing dosing regimens; in pharmacodynamic studies, it assesses the therapeutic effects on disease models.

• Quality Control：Used for UPLC-MS/MS detection of Deucravacitinib in active pharmaceutical ingredients and formulations, controlling impurity content to meet ICH Q3A and Q3B standards, ensuring drug quality and safety.

Background Description

Deucravacitinib is an innovative oral small-molecule drug targeting tyrosine kinase 2 (TYK2). Autoimmune diseases such as psoriasis and rheumatoid arthritis are closely related to the abnormal activation of signaling pathways within immune cells. As a key signaling molecule, TYK2 is involved in the signal transduction of cytokines such as interferons and interleukins. Traditional therapeutic drugs have limitations in efficacy and significant side effects. Deucravacitinib specifically binds to the regulatory domain of TYK2, blocking its activation and avoiding widespread inhibition of other kinases, thus enabling more precise and safe immune regulation and bringing new directions for the treatment of autoimmune diseases.

Research Status

• Clinical Application Progress：Approved for the treatment of psoriasis. Data from multiple Phase III clinical trials show that it significantly improves patients' skin symptoms and quality of life compared with placebo; clinical trials for rheumatoid arthritis, systemic lupus erythematosus, and other diseases are ongoing to explore broader indications.

• In-Depth Mechanism Research：The binding mode of Deucravacitinib to the TYK2 protein is analyzed by cryo-electron microscopy to clarify the molecular mechanism of its highly selective inhibition; gene editing techniques are used to knock down or overexpress TYK2 to further verify its regulatory effect on downstream signaling pathways.

• Formulation Optimization：Research on new formulation technologies, such as nanoparticle delivery systems and sustained-release formulations, to improve drug bioavailability and patient compliance; evaluate the release characteristics and stability of different formulations in vitro and in vivo to provide better choices for clinical applications